$JVSA
JVSPAC Acquisition Corp.

2024 Q2 Form 10-Q Financial Statement

#000121390024042289 Filed on May 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $327.5K $233.3K $26.57K
YoY Change 24524.81% 4328.33%
Operating Profit -$327.5K -$233.3K
YoY Change 49372.81% 35085.52%
Interest Expense $768.7K $100.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income $441.2K $331.0K -$26.57K
YoY Change -33271.43% 4328.33%
Income Tax
% Of Pretax Income
Net Earnings $441.2K $331.0K -$26.57K
YoY Change -66743.81% -50018.7% 4328.33%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.06 $0.04 $0.00
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $59.73M $59.11M
YoY Change
Cash & Equivalents $1.047M $1.047M
Short-Term Investments $58.82M $58.06M
Other Short-Term Assets $175.8K $356.3K $394.4K
YoY Change -39.37%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.086M $1.404M $7.650K
YoY Change 274.61%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $58.82M $58.06M $386.7K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $1.086M $1.404M $7.650K
Total Long-Term Assets $58.82M $58.06M $386.7K
Total Assets $59.90M $59.46M $394.4K
YoY Change 20562.7% 66.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $89.37K $92.23K $5.312K
YoY Change -51.71%
Accrued Expenses $70.00K $70.00K $200.0K
YoY Change -46.89% 72.75%
Deferred Revenue
YoY Change
Short-Term Debt $286.4K $286.4K $286.4K
YoY Change 105.3%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $445.8K $448.6K $491.7K
YoY Change 64.3% 90.72%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $445.8K $448.6K $491.7K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $445.8K $448.6K $491.7K
YoY Change 64.31%
SHAREHOLDERS EQUITY
Retained Earnings $649.8K $208.6K -$122.3K
YoY Change 168.87%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.027M $4.444M -$97.32K
YoY Change
Total Liabilities & Shareholders Equity $59.90M $59.46M $394.4K
YoY Change 20562.7% 66.18%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q4
OPERATING ACTIVITIES
Net Income $441.2K $331.0K -$26.57K
YoY Change -66743.81% -50018.7% 4328.33%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$137.0K -$490.1K $0.00
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 -$57.50M
YoY Change
Cash From Investing Activities $0.00 $57.50M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 $59.04M
YoY Change
NET CHANGE
Cash From Operating Activities -137.0K -$490.1K 0.000
Cash From Investing Activities 0.000 $57.50M
Cash From Financing Activities 0.000 $59.04M
Net Change In Cash -137.0K $116.0M 0.000
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$137.0K -$490.1K $0.00
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-41922
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
JVSPAC ACQUISITION CORP.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
D8
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
G/F Hang Tak Building
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
1 Electric Street
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Wan Chai
CY2024Q1 dei Entity Address Country
EntityAddressCountry
HK
CY2024Q1 dei City Area Code
CityAreaCode
(+852)
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
9258 9728
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
true
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1047202 usd
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
356344 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7650 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
1403546 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
7650 usd
CY2023Q4 us-gaap Deferred Costs
DeferredCosts
386725 usd
CY2024Q1 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
58059296 usd
CY2024Q1 us-gaap Assets
Assets
59462842 usd
CY2023Q4 us-gaap Assets
Assets
394375 usd
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
92234 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5312 usd
CY2024Q1 jvsa Accrued Offering Costs
AccruedOfferingCosts
70000 usd
CY2023Q4 jvsa Accrued Offering Costs
AccruedOfferingCosts
200000 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
448619 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
491697 usd
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4210046 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
208639 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-122322 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
4443685 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-97322 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
59462842 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
394375 usd
CY2024Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
233280 usd
CY2023Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
663 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-233280 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-663 usd
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
559296 usd
CY2024Q1 us-gaap Interest Income Other
InterestIncomeOther
4945 usd
CY2024Q1 us-gaap Other Income
OtherIncome
564241 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
330961 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-663 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-97322 usd
CY2024Q1 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
83035 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2676965 usd
CY2024Q1 jvsa Sale Of Placement Units
SaleOfPlacementUnits
240000 shares
CY2024Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
2378187 usd
CY2024Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
632284 usd
CY2024Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1477390 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
330961 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
4443685 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-20495 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-663 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-21158 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
330961 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-663 usd
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
559296 usd
CY2023Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
663 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
348694 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
86922 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-490107 usd
CY2024Q1 us-gaap Payments To Acquire Trust Preferred Investments
PaymentsToAcquireTrustPreferredInvestments
57500000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-57500000 usd
CY2024Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
57500000 usd
CY2024Q1 jvsa Payment Of Underwriting Commissions
PaymentOfUnderwritingCommissions
575000 usd
CY2024Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
2400000 usd
CY2024Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
287691 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
59037309 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1047202 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1047202 usd
CY2024Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1477390 usd
CY2024Q1 jvsa Offering Costs Included In Accrued Offering Costs
OfferingCostsIncludedInAccruedOfferingCosts
70000 usd
CY2024Q1 us-gaap Stock Issued1
StockIssued1
632284 usd
CY2024Q1 jvsa Purchase Additional Units
PurchaseAdditionalUnits
750000 shares
CY2024Q1 jvsa Underwriting Commissions Paid
UnderwritingCommissionsPaid
575000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
632284 usd
CY2024Q1 jvsa Other Offering Costs
OtherOfferingCosts
544416 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
57500000 usd
CY2024Q1 us-gaap Share Price
SharePrice
10
CY2024Q1 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
1 pure
CY2024Q1 us-gaap Investment Company Total Return Market Value
InvestmentCompanyTotalReturnMarketValue
0.80 pure
CY2024Q1 us-gaap Stock Option Exercise Price Increase
StockOptionExercisePriceIncrease
0.2
CY2024Q1 us-gaap Shares Issued
SharesIssued
5750000 shares
CY2024Q1 us-gaap Interest Expense
InterestExpense
100000 usd
CY2024Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
10
CY2024Q2 us-gaap Exchange Fees
ExchangeFees
30935563 usd
CY2024Q2 jvsa Generating Gross Proceeds
GeneratingGrossProceeds
2300000000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1047202 usd
CY2024Q1 jvsa Working Capital
WorkingCapital
954927 usd
CY2024Q1 us-gaap Payments For Loans
PaymentsForLoans
350000 usd
CY2024Q1 us-gaap Other Borrowings
OtherBorrowings
286385 usd
CY2024Q1 jvsa Allocation Of Offering Cost Related To Redeemable Sharesin Shares
AllocationOfOfferingCostRelatedToRedeemableSharesinShares
-1646852 usd
CY2024Q1 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
1477390 usd
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the condensed financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p>
CY2024Q1 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
1047202 usd
CY2023Q4 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
0 usd
CY2024Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
1751700 usd
CY2024Q1 jvsa Temporary Equity Charge
TemporaryEquityCharge
1646852 usd
CY2024Q1 jvsa Shareholders Equity Charged
ShareholdersEquityCharged
104848 usd
CY2024Q1 jvsa Generating Gross Proceeds
GeneratingGrossProceeds
57500000 usd
CY2024Q1 jvsa Temporary Equity Accretion To Allocated To Public Rights
TemporaryEquityAccretionToAllocatedToPublicRights
-2760000 usd
CY2024Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
54570538 usd
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Concentration of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts.</p>
CY2024Q1 us-gaap Malpractice Insurance Coverage Floor
MalpracticeInsuranceCoverageFloor
250000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
330961 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-663 usd
CY2024Q1 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
1477390 usd
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1146429 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-663 usd
CY2024Q1 jvsa Underwriting Fee
UnderwritingFee
575000 usd
CY2024Q1 jvsa Other Offering Costs
OtherOfferingCosts
544416 usd
CY2024Q1 jvsa Private Placement Abstract
PrivatePlacementAbstract
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 4 — Private Placement</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Simultaneously with the closing of the IPO and the over-allotment, the Sponsor purchased an aggregate of 240,000 private placement units at a price of $10.00 per unit for an aggregate purchase price of $2,400,000. Each Private Placement Unit was identical to the units sold in the IPO, except as described below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Founder Shares, private placement shares or private placement rights. The rights will expire worthless if the Company does not consummate a Business Combination within the allotted 12-month period (or up to 18 months from the completion of the IPO if the Company extends the period of time to consummate a Business Combination by the full amount of time).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The private placement units, private placement shares, private placement rights and the Class A ordinary shares underlying such rights will not be transferable, assignable or salable by the Sponsor until thirty (30) days after the completion of the Company’s initial Business Combination, except to permitted transferees.</p>
CY2024Q1 jvsa Aggregate Purchase Price
AggregatePurchasePrice
10
CY2024Q1 us-gaap Loans Payable
LoansPayable
350000 usd
CY2024Q1 us-gaap Origination Of Notes Receivable From Related Parties
OriginationOfNotesReceivableFromRelatedParties
286385 usd
CY2024Q1 jvsa Working Capital Loans
WorkingCapitalLoans
1150000 usd
CY2024Q1 us-gaap Preferred Stock Convertible Conversion Price
PreferredStockConvertibleConversionPrice
10
CY2024Q1 us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
1000 usd
CY2024Q1 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
3000 usd
CY2024Q1 jvsa Exercised Per Share
ExercisedPerShare
0.1
CY2024Q1 jvsa Maximum Number Of Demands For Registration Of Securities
MaximumNumberOfDemandsForRegistrationOfSecurities
3 pure
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2021Q2 jvsa Initial Shareholder
InitialShareholder
25000 shares
CY2021Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.017
CY2024Q1 us-gaap Assets Held In Trust Current
AssetsHeldInTrustCurrent
58059296 usd
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
usd
CY2024Q1 us-gaap Deferred Costs
DeferredCosts
usd
CY2023Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
usd
CY2023Q1 us-gaap Other Income
OtherIncome
usd
CY2024Q1 jvsa Net Of Issuance Costs
NetOfIssuanceCosts
22815 usd
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
usd
CY2024Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
usd
CY2023Q1 us-gaap Payments To Acquire Trust Preferred Investments
PaymentsToAcquireTrustPreferredInvestments
usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2023Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
usd
CY2023Q1 jvsa Payment Of Underwriting Commissions
PaymentOfUnderwritingCommissions
usd
CY2023Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
usd
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
CY2023Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
usd
CY2023Q1 jvsa Offering Costs Included In Accrued Offering Costs
OfferingCostsIncludedInAccruedOfferingCosts
usd
CY2023Q1 us-gaap Stock Issued1
StockIssued1
usd
CY2023Q1 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
usd
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
N/A
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001866001

Files In Submission

Name View Source Status
0001213900-24-042289-index-headers.html Edgar Link pending
0001213900-24-042289-index.html Edgar Link pending
jvsa-20240331_def.xml Edgar Link unprocessable
jvsa-20240331_pre.xml Edgar Link unprocessable
0001213900-24-042289.txt Edgar Link pending
0001213900-24-042289-xbrl.zip Edgar Link pending
ea0205516-10q_jvspacacq.htm Edgar Link pending
ea020551601ex31-1_jvspac.htm Edgar Link pending
ea020551601ex31-2_jvspac.htm Edgar Link pending
ea020551601ex32-1_jvspac.htm Edgar Link pending
ea020551601ex32-2_jvspac.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
jvsa-20240331.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
jvsa-20240331_cal.xml Edgar Link unprocessable
jvsa-20240331_lab.xml Edgar Link unprocessable
ea0205516-10q_jvspacacq_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable